Protagonist Therapeutics Delivers Positive Topline Results in Psoriasis Study

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) has received positive topline results in its Phase 2b FRONTIER 1 clinical trial evaluating a treatment for psoriasis. The study is being conducted in collaboration with Janssen Biotech, Inc. The company’s candidate, JNJ-2113, is an oral Interleukin-23 receptor (IL-23R) antagonist peptide. IL-23 inhibitors can help limit the inflammation that causes… [Read More]

Unicycive Successfully Raises $130M To Launch Renazorb For Dialysis Patients

Unicycive Therapeutics, Inc., (Nasdaq: UNCY) has raised up to $130M to support its New Drug Application (NDA) submission with the FDA for approval and potential commercial launch of Renazorb for the treatment of hyperphosphatemia. The securities purchase agreement includes initial upfront funding of $30M and up to an additional $100M tied to achievement of milestones…. [Read More]

BridgeBio Reports Positive Phase 2 Results; Begins Enrolling Patients in Phase 3 Study

Commercial-stage biopharmaceutical company, BridgeBio (Nasdaq: BBIO), has announced positive results from its PROPEL2 Phase 2 clinical trial demonstrating potential best-in-class efficacy and a clean safety profile for its investigational therapy, infigratinib. The company is assessing infigratinib as a treatment in children with achondroplasia, a genetic bone growth disorder that results in dwarfism. Highlights  80% of… [Read More]

Meta Shares Rise 6% As Company Reduces Prices on VR Headsets

Shares of Meta Platforms (META) rose by 6% after the company announced significant price cuts for its virtual reality (VR) headsets. The cost of the Quest 2 will be reduced by $70 to $429.99, while the price of the Quest Pro will drop to $999.99 from $1,499.99. The new pricing for Quest 2 will be… [Read More]

Lexaria’s Diabetes Study Results Feature Weight Loss and Improved Triglyceride and Cholesterol Levels

Lexaria Bioscience (NASDAQ: LEXX) shared the notable results of its recent diabetes animal model study, with positive outcomes including weight loss and improved triglyceride and cholesterol levels in obese diabetic-conditioned animals who were dosed with DehydraTECH-CBD. The growing global diabetes drug market is anticipated to reach nearly $83 billion by 2027, and the bioscience company’s… [Read More]

Incannex Inks Manufacturing Agreement for Psilocybin Drug Product

Incannex Healthcare Limited (Nasdaq: IXHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged a manufacturer for the development and production of its psilocybin drug product. Catalent Australia will develop and manufacture a cGMP-grade psilocybin drug product for use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development… [Read More]